Dexmethylphenidate: Tackling Attention Deficit Hyperactivity Disorder

Drug Overview:

Dexmethylphenidate is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD). Its mechanism of action involves modifying the levels of specific natural chemicals in the brain. Dexmethylphenidate is categorized as a stimulant medication. Its primary effects include enhancing attention span, sustaining concentration on tasks, and managing behavioral challenges. Moreover, it might facilitate task organization and contribute to the enhancement of listening capabilities. The US FDA (the United States Food and Drug Administration) approved Dexmethylphenidate as a medication on May 26, 2005, for the treatment of ADHD.

For Patients:

What Is Attention Deficit Hyperactivity Disorder?

Attention deficit hyperactivity disorder (ADHD) stands as one of the prevalent neurodevelopmental disorders in childhood, frequently identified during this stage and persisting into adulthood. Those affected by ADHD in childhood could encounter challenges in maintaining attention, managing impulsive actions (potentially engaging without considering the consequences), or displaying excessive levels of activity.

What Are the Clinical Indications For Dexmethylphenidate?

Dexmethylphenidate forms an integral component of a therapeutic regimen aimed at managing the symptoms of attention deficit hyperactivity disorder (ADHD) in both adults and children. Within the classification of pharmaceuticals known as central nervous system (CNS) stimulants, Dexmethylphenidate operates by elevating the levels of specific naturally occurring compounds within the brain. These actions contribute to alleviating challenges such as heightened difficulty in maintaining focus, regulating actions, and exhibiting stillness or calmness, particularly when compared to peers of the same age.

How Should One Use This Medication?

• Dexmethylphenidate is available in tablet and extended-release capsule forms for oral consumption. The tablet is typically taken twice daily, with a minimum interval of four hours, with or without food. Alternatively, the extended-release capsule is usually taken once each morning. Optimal effectiveness is achieved when the capsule is taken without food. It is advised to take Dexmethylphenidate at the same time(s) daily. Precise adherence to the prescription instructions is crucial; any unclear aspects should be discussed with a medical professional.

• The extended-release capsules must be swallowed whole, avoiding chewing or crushing. If swallowing is difficult, carefully opening the capsule and sprinkling its contents onto a spoonful of applesauce is an option. This mixture should be swallowed immediately, without chewing, and should not be stored for later use.

• The treatment typically starts with a low Dexmethylphenidate dose, which may be gradually increased, generally not more frequently than once a week.

• Expect improvements in the condition during the treatment course. Contact the doctor if symptoms worsen or fail to improve after a month of treatment.

What Are the Things to Inform the Doctor Before Taking the Drug?

• Allergic Reactions and Medications: Before taking Dexmethylphenidate, individuals should inform their doctor and pharmacist about any allergies to Dexmethylphenidate, Methylphenidate, or other medications. They should also mention if they are taking or have taken monoamine oxidase inhibitors (MAOIs) within the past 14 days, as Dexmethylphenidate should not be taken in conjunction with these medications.

• Medication Interactions: It is important to disclose all prescription and nonprescription medications, vitamins, supplements, and herbal products being taken. Specific medications like anticoagulants, antidepressants, decongestants, diuretics, blood pressure medications, and others should be mentioned to the doctor.

• Tourette's Syndrome and Tics: Individuals with a history of Tourette's syndrome, motor tics, facial tics, or verbal tics should inform their doctor. Also, individuals with glaucoma or feelings of anxiety, tension, or agitation should not take Dexmethylphenidate.

• Heart Conditions: Those with a history of irregular heartbeat, sudden death in the family, recent heart attack, heart defects, high blood pressure, or other heart problems need to let their doctor know. Dexmethylphenidate may not be suitable for individuals with heart conditions.

• Mood Disorders and Mental Health: A history of depression, bipolar disorder, mania, suicidal thoughts, mental illness, seizures, abnormal EEG (electroencephalogram) results, or thyroid disease should be communicated to the doctor.

• Pregnancy and Breastfeeding: Before taking Dexmethylphenidate, women who are pregnant, want to become pregnant, or who are breastfeeding should talk to their doctor.

What Are the Side Effects of Dexmethylphenidate?

Dexmethylphenidate can potentially lead to the occurrence of side effects. Individuals are advised to inform their healthcare provider if any of these symptoms become severe or persist:

• Nausea.

• Dry mouth.

• Heartburn.

• Weight loss.

• Headache.

• Drowsiness.

• Dizziness.

• Nervousness or jitteriness.

Certain side effects need serious attention. Should any of the following symptoms arise, it is recommended to promptly contact a medical professional:

• Dizziness.

• Excessive tiredness.

• Changes in vision or blurred vision.

• Weakness or numbness of a leg or arm.

• Seizures.

• Heightened suspicion of others that is unusual.

• Slow or difficult speech.

• Holding false beliefs.

• Hallucinations (visual or auditory perceptions without external stimulus).

• Mood alterations.

• Depression.

• Motor or verbal tics.

• Swelling of the face, tongue, throat, eyes, or lips.

• Rash.

• Hives.

• Itching.

• Purple blotches under the skin.

• Fever.

• Unexplained wounds on fingers or toes.

• Blistering or peeling skin.

• Joint pain.

• Frequent, painful erections.

• Prolonged erection lasting over four hours.

• Numbness, pain, or sensitivity to temperature in fingers or toes.

• Change in skin color in fingers or toes from pale to blue to red.

It is crucial to note that Dexmethylphenidate could result in sudden death in children and teenagers, particularly those with heart defects or significant heart issues. Adults, especially those with major cardiac conditions or heart defects, who take this medicine carry the risk of stroke, heart attack, or sudden death. While taking this drug, a doctor should be contacted right away if any heart-related symptoms, such as chest pain, breathlessness, or fainting, appear.

The associated risks of using this medication should be discussed with a healthcare provider.

In children, Dexmethylphenidate may potentially impede growth or weight gain. Regular monitoring of a child's growth by a physician is recommended. Any concerns about a child's growth or weight while on this medication should be discussed with the child's doctor. The potential risks of administering Dexmethylphenidate to a child should also be addressed with a healthcare provider.

Additional side effects could also arise from Dexmethylphenidate usage. Should any unusual issues be experienced while taking this medication, it is advisable to contact a doctor.

• Missed Dose: In case a dose of the medication is missed, the individual should take it promptly when remembered. However, it is advisable to ignore the missed dose and resume the regular dosing plan if the next scheduled dose is soon to be administered. Doubling the dosage should be avoided.

• Overdose: When a victim experiences collapse, seizures, breathing difficulties, or unresponsiveness, it is crucial to promptly contact emergency services. Overdose symptoms encompass various indicators such as vomiting, agitation, involuntary body tremors, muscle spasms, seizures, loss of consciousness, excessive happiness, confusion, hallucinations, sweating, flushing, headaches, fever, rapid or irregular heartbeat, dilated pupils, and dry mouth.

• Storage: The medication should be retained within its original container, sealed securely, and positioned out of the grasp of children. It needs to be stored at room temperature, avoiding excessive heat and moisture (refrain from storing it in the bathroom).

Maintaining the safety of children is of utmost importance. Numerous types of containers, including weekly pill organizers, as well as those for products like eye drops, creams, patches, and inhalers, might lack child-resistant features, allowing young children to open them effortlessly. To safeguard against potential poisoning, it is advised to consistently lock safety caps and promptly relocate the medication to a secure location – one that is elevated, distant, and beyond the visual and physical reach of children.

For Doctors:

Indication: Dexmethylphenidate is prescribed for managing attention deficit hyperactivity disorder (ADHD) in individuals who are six years of age and older.

Dosing Considerations:

Dosage must be tailored to individual patient's needs and responses.

• Patients New to Methylphenidate: Pediatric patients start with 5 mg/day (milligram per day), adults start with 10 mg/day, with adjustments in 5 mg (milligrams) increments for pediatric and 10 mg increments for adult patients, observing effects before increasing.

• Patients Currently Using Methylphenidate: Start Dexmethylphenidate at half the total daily dose of racemic Methylphenidate; Dexmethylphenidate users can switch to the same daily dose.

• Insufficient conclusive evidence exists regarding the optimal duration of Dexmethylphenidate treatment for individuals with ADHD; while extended therapy might be warranted, it is recommended that regular reevaluation be conducted.

• Reduction or discontinuation of dosage if symptoms worsen or adverse events occur.

• If there is no improvement after one month of dosage adjustment, consider discontinuing the drug.

• Available in various extended-release capsule strengths from five mg to 40 mg.

What Are the Pharmacological Aspects of Dexmethylphenidate?

Mechanism Of Action

Dexmethylphenidate hydrochloride operates as a central nervous system stimulant. It is the potent d-enantiomer of racemic Methylphenidate, working to hinder the reuptake of Norepinephrine and dopamine into the presynaptic neuron. This leads to heightened release of these neurotransmitters into the extraneuronal area. Despite its effectiveness in treating attention deficit hyperactivity disorder (ADHD), the precise therapeutic mechanism remains unclear.

Pharmacokinetics

• Absorption: Whether Dexmethylphenidate is taken with or without food, its clinical impact remains unaffected. Approximately 90 percent of an oral dose gets absorbed. Still, due to hepatic first-pass metabolism, its oral bioavailability is only 23 percent, whereas l-methylphenidate has a lower oral bioavailability of five percent. The peak concentration is typically achieved within one to 1.5 hours after administration.

• Protein Binding: Dexmethylphenidate's protein binding percentage varies between 12 - 15 percent, as indicated by one study. Nevertheless, alternate research has reported slightly higher figures of 15.2±5.2 percent for children and 16.2±1.1 percent for adults.

• Metabolism: In the liver, carboxylesterase 1A1 plays a pivotal role in metabolizing Dexmethylphenidate into the inactive metabolite ritalinic acid. Additional minor pathways also contribute to the metabolism, producing inactive metabolites such as 6-oxo-methylphenidate and p-hydroxy-methylphenidate. These metabolites undergo de-esterification and conjugation, ultimately forming unidentified metabolites through these alternative pathways.

• Excretion: In the context of renal elimination, Dexmethylphenidate demonstrates significant excretion through urine. Approximately 90 percent of the administered dose can be found in the urine after 48 hours, with a minor 3.3 percent being recovered from fecal matter.

Overdosage:

1. Signs and Symptoms of Overdosage:

• Acute Methylphenidate overdose leads to CNS overstimulation and excessive sympathomimetic effects.

• Symptoms include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may lead to coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia (high fever), tachycardia (rapid heartbeat), palpitations, cardiac arrhythmias, hypertension (high blood pressure), mydriasis (dilated pupils), and dryness of mucous membranes.

• Rhabdomyolysis (muscle breakdown) can also occur in overdose.

2. Recommended Treatment:

• When managing overdose, the possibility of multiple drug ingestion should be considered.

• Supportive measures are essential, including protection against self-injury and stimuli that worsen overstimulation.

• Gastric contents can be removed through gastric lavage, if necessary, after controlling agitation and seizures and ensuring airway protection.

• Other gut detoxification methods include activated charcoal and a cathartic.

• Intensive care is necessary to maintain proper circulation and breathing; hyperpyrexia may require external cooling.

• Peritoneal dialysis efficacy for Focalin overdose has not been established.

Clinical Studies And Efficacy:

Dexmethylphenidate's effectiveness in treating ADHD has been established through controlled studies involving both children and adolescents, as well as adults meeting the DSM-IV criteria for ADHD. Dexmethylphenidate showed a substantial treatment benefit in comparison to placebo in research, including 103 pediatric kids between the ages of six and seventeen who were given flexible dosages of the medication over the course of seven weeks. Although the study had insufficient adolescents to assess efficacy, evidence from immediate-release Dexmethylphenidate and pharmacokinetic considerations support its effectiveness in this age group. Additionally, studies in pediatric patients aged six to 12 receiving 20 mg of Dexmethylphenidate demonstrated its consistent treatment effect on specific classroom behaviors related to attention and behavior. In a separate study with 221 adult patients aged 18 to 60, Dexmethylphenidate at different doses (20, 30, and 40 mg/day) was found to be significantly superior to placebo in treating ADHD symptoms. Notably, there was no evident increase in effectiveness with higher doses.

What Are the Contraindications to Dexmethylphenidate?

• Agitation: Dexmethylphenidate must not be used in patients exhibiting marked anxiety, tension, and agitation, as the drug may worsen these symptoms.

• Hypersensitivity to Methylphenidate: Dexmethylphenidate is contraindicated in patients who are hypersensitive to Methylphenidate or any components of the product. Methylphenidate patients have experienced hypersensitivity events such as anaphylactic reactions and angioedema.

• Glaucoma: Dexmethylphenidate should not be administered to patients with glaucoma.

• Tics: Dexmethylphenidate is not suitable for patients with motor tics or those with a family history or diagnosis of Tourette’s syndrome.

• Monoamine Oxidase Inhibitors: Dexmethylphenidate is contraindicated while undergoing treatment with monoamine oxidase inhibitors (MAOIs). Usage of Dexmethylphenidate within at least 14 days after discontinuing MAOI treatment is prohibited due to the risk of hypertensive crises.

Warnings and Precautions:

Sudden Death and Preexisting Structural Cardiac Abnormalities or Other Serious Heart Problems:

• Children and Adolescents

  • Sudden death associated with CNS stimulant treatment was reported in children with heart issues.

  • Stimulants should not be used in kids with serious heart abnormalities, cardiomyopathy, or rhythm issues.

• Adults

  • Sudden death, stroke, and heart attack were reported in adults taking stimulants for ADHD.

  • Stimulants are not recommended for adults with heart problems or cardiac abnormalities.

• Hypertension and Other Cardiovascular Conditions

  • Stimulants raise blood pressure and heart rate.

  • Caution is needed for patients with hypertension, heart failure, or heart rhythm issues.

• Assessing Cardiovascular Status

  • Patients considered for stimulant treatment should have cardiac evaluation.

  • History, physical exam, ECG, and echocardiogram may be required.

  • Prompt evaluation if symptoms like chest pain occur during treatment.

• Preexisting Psychosis

  • Stimulants may worsen behavior and thought issues in those with psychotic disorders.

• Bipolar Illness

  • Care is needed when treating ADHD in patients with bipolar disorder.

  • Screen for bipolar risk, including family history.

• Emergence of New Psychotic or Manic Symptoms

  • Stimulants can cause hallucinations, delusions, or mania in children.

  • Consider discontinuation if such symptoms appear.

• Aggression

  • ADHD patients may show aggression or hostility.

  • Monitor for worsening upon starting treatment.

• Long-Term Suppression of Growth

  • Consistently medicated children may have slower growth temporarily.

  • Growth should be monitored, and interruption of treatment may be needed.

• Seizures

  • Stimulants may lower the seizure threshold in some patients.

  • Discontinue if seizures occur.

• Priapism

  • Painful, prolonged erections were reported with stimulant use.

  • Seek medical attention if sustained erections happen.

• Peripheral Vasculopathy, Including Raynaud’s Phenomenon

  • Stimulants associated with peripheral vasculopathy.

  • Raynaud's phenomenon was observed, but careful observation was required.

• Visual Disturbance

  • Blurring of vision and accommodation issues were reported with stimulants.

• Use in Children Under Six Years of Age

  • Dexmethylphenidate is not recommended for children under six due to a lack of safety and efficacy data.

• Hematologic Monitoring

  • Periodic blood tests are advised during prolonged stimulant therapy.

Use in Specific Populations:

• Pregnancy Considerations for Dexmethylphenidate:

  • Pregnancy Category C: There are no well-controlled studies of Dexmethylphenidate in pregnant women. While no major malformations occurred in rats or rabbits, delayed skeletal ossification and reduced weight gain were noted in rats. Use during pregnancy should be based on balancing potential benefits and risks to the fetus.

  • Animal Studies: Dexmethylphenidate, the active ingredient, was administered to rats and rabbits during organogenesis without causing birth defects. However, delayed skeletal ossification was observed in rats at the highest dose.

  • Postweaning Effects: In rat studies, Dexmethylphenidate administration during pregnancy and lactation reduced post-weaning weight gain in male offspring at higher doses, with no other developmental effects noted.

• Labor and Delivery: Dexmethylphenidate's effects during labor and delivery have not been investigated.

• Nursing Mothers: Dexmethylphenidate excretion in human milk is uncertain. Caution is advised if Dexmethylphenidate is given to nursing women. Limited data on racemic methylphenidate suggest small amounts in breast milk, with calculated infant daily doses ranging from 0.4 to 2.9 µg/kg/day (microgram per kilogram body weight per day).

• Pediatric Use:

  • Age Limit: Dexmethylphenidate's safety and efficacy have not been established in children under six years old.

  • Long-term Effects: Long-term effects of Dexmethylphenidate in children are unclear. A study on rats exposed to racemic Methylphenidate showed decreased locomotor activity and learning deficits in those receiving high doses.

• Geriatric Use: Dexmethylphenidate's use has not been studied in the geriatric population.

• Hepatic Insufficiency: Information on Dexmethylphenidate use in patients with hepatic insufficiency is lacking.